Bavarian Nordic

This morning we released our financial results for the first three months. We saw an increasing demand for travel vaccines and added more customers to our public preparedness business, as more governments are taking proactive measures to prevent future pox outbreaks. 🙏🏼 💉 We asked our CEO Paul Chaplin to reflect on the highlights of the first three months in this video 👇🏼 If you want to read more follow this link for our quarterly financial report here --> https://bit.ly/4dxrg34 #press #vaccines #financialreporting #savinglives #protectingcommunities

Today, we announced our financial results for the first quarter of 2024. -         Our travel health business continues to demonstrate strong performance, growing 20% in revenues vs. Q1 2023. -         We maintain our financial guidance for the full year, expecting revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million. -         Highlights from the quarter include the commercial launch of our #mpox vaccine in the U.S. and the initiation of a rolling BLA submission for our #chikungunya vaccine candidate with the FDA. We are on track to complete regulatory submissions in the U.S. and the EU by June 2024. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We are pleased to report continued strong performance in our travel health business, reflecting market growth and a strong brand performance from our leading portfolio of vaccines. Over the next couple of months, we are finalizing our submissions to the U.S. and European regulatory authorities for approval of our chikungunya vaccine, which represents a significant future asset for the travel health business upon expected launch in 2025. We have also successfully launched our mpox vaccine in the U.S. during April and are working with healthcare providers and advocacy groups to enhance awareness and provide a broader access to the vaccine for at-risk populations. This will further diversify our public preparedness business, as we continue to expand orders with both existing and new customers following the 2022-2023 mpox outbreak to support nations in strengthening their smallpox preparedness. Our first quarter reflects the usual seasonality in travel vaccines combined with phasing of our deliveries of smallpox/mpox vaccines towards the end of the year, thus reaffirming our guidance for 2024 with revenues between DKK 5 to 5.3 billion.” Read the full report: https://bit.ly/4dxrg34

Hi, I am Zacharias Søgaard Nielsen, and I am a Shutdown Lead at Bavarian Nordic.     As a Shutdown Lead, I contribute to ensuring planned production stops are done successfully, which takes team effort and collaboration. It makes me proud to experience the #BoostedByTheTeam spirit resulting in a successful production upstart!   I find the culture here at Bavarian Nordic, quite inclusive. To me, inclusiveness is when everyone is very open-minded and helpful. When performing work concerning the production areas, everyone is ready to step up and help, even though they have a lot on their plate. If you want to join me in Bavarian Nordic, check out our open positions: https://lnkd.in/eG9TCbF #BavarianNordicDNA #pharma #inclusion

We are pleased to announce the initiation of the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of our #chikungunya vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older.

Do you recycle? ♻ Last week our colleague Anne Krongaard represented Bavarian Nordic on stage at the leading Nordic responsible use conference LOOP Forum addressing how we incorporate recycling into our business. In 2023 we managed to recycle more than 50% of our resources used in our global manufacturing. This was despite a significantly higher production level and adding a new manufacturing site to our environmental accounting. Of new recycling initiatives we particularly focus on recycling options for mixed plastics, and recycling of glass from vaccine vials that have been discarded. Read more in our 2023 sustainability report --> https://bit.ly/3UCUu9i

Reporting live from #ESCMIDGlobal! Stop by our Bavarian Nordic booth (D21) and make sure to join us at our symposium today at 4pm CET on how real-world effectiveness data can impact vaccination strategies and visit our team in Barcelona until April 30, 2024.    #ECCMID2024 #BavarianNordic #Vaccines #boostedbytheteam 

Meet us in Barcelona! You are invited to our #ESCMIDGlobal industry symposium ‘When vaccine efficacy cannot be studied: How real-world effectiveness data can impact vaccination strategies’. Join our expert speakers this Saturday as we spotlight #chikungunya, #mpox, and tick-borne encephalitis.      🕓 :     4:00 – 5:30 PM CET  📅 :    27 April 2024  📍:        Hall 0, Fira Gran Via, Barcelona    #ECCMID2024 #BavarianNordic #VaccinesWork #PioneeringVaccines

This #WorldImmunizationWeek, we celebrate the life-saving power of vaccines.  At Bavarian Nordic, our teams work tirelessly to improve the efficacy, safety, and accessibility of vaccines. As one of the leading pure-play vaccine companies, we celebrate the life-saving power of vaccines, one of the most formidable tools in public health -saving millions of lives every year.    We extend our hand to partners, healthcare professionals, and communities worldwide. Together, we make it humanly possible to protect and save lives through immunization. #WorldImmunizationWeek2024 #WHO #VaccinesWork #ProtectingOurTomorrow #ProtectingLivesEveryDay #PioneeringVaccines #HumanlyPossible

Join us in Bavarian Nordic! We are currently looking for many new colleagues to join us at our Manufacturing site in Kvistgaard, Denmark. Take a look at our vacant positions here: https://lnkd.in/eG9TCbF #Hiring #BoostedbytheTeam #RampUp